REFERENCES
- Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris, London. New Sydenham Society 1865; 3: 94.
- Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and exces-sive fibrinolysis in a patient with metastatic prostate cancer. Cancer 1992; 70: 656 — 8.
- Pogliani EM, Fowst C, Maffe P, etal. CNS metas-tasis in ovarian cancer with microangiopathic hemolytic anemia associated with diffuse intravas-cular coagulation. Tumori 1988; 74: 731 —6.
- Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, et al. Abnormal-ities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596 — 602.
- Wersch van JWJ, Peters C, Ubachs JMH. Haemos-tasis in benign and malignant gynaecological tumours: a pilot study. Eur J Clin Chem Clin Biochem 1995; 33: 225–9.
- Edwards CM, Warren J, Armstrong L, Donnelly PK. D-dimer: a useful marker of disease in sur-gery for colorectal cancer. Br J Surg 1993; 80: 1404 — 5.
- Olt GJ, Greenberg C, Synan I, Coleman RE, Clarke-Pearson D. Preoperative assessment of fragment D-dimer as a predictor of postoperative venous thrombosis. Am J Obstet Gynecol 1990; 162: 772 — 5.
- Gaducci A, Baicchi U, Marrai R, Facchini V, Del Bravo B, Fosella PV, Fioretti P. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol 1992; 49: 354 — 8.
- Van Duijnhoven EM, Lustermans FAT, van Wersch JWJ. Evaluation of the coagulation /fibri-nolysis balance in patients with colorectal cancer. Haemostasis 1993; 23: 168 — 72.
- Bick RL. Antithrombin III and factor VIII in patients with neoplasms. Am J Clin Path 1978; 69: 194 — 5.
- Dvorak HF. Abnormalities of hemostasis in malig-nant disease. In: Colman RW, Hirsch J, Marder VJ, Salzmann EW, editors. Hemostasis and thrombo-sis, basic principles and clinical practice, 3rd ed. Philadelphia: J. B. Lippincott, 1993: 1238 — 50.
- Schmitt M, Harbeck N, Thomssen C, Wilhelm 0, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasmi-nogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285 — 96.
- Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk J. Tumor cell procoagulant and urokinase expression in carci-noma of the ovary. J Natl Cancer Inst 1993; 85: 1225 — 30.
- Honegger H, Anderson N, Hewitt LA, Tullis J L. Antithrombin III profiles in malignancy, relation-ship to primary tumors and metastatic sites. Thromb Haemost 1981; 46: 500 — 3.
- Mirshahi SS, Puja de Lauraine E, Soria C, Mirshahi M, Fretault J, Bernadou A, Soria J. D-dimer and CA125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti cancer treatment. Cancer 1992; 69: 2289–92.
- Gaducci A, Baicchi U, Marrai R, Del Bravo B, Fossela PV, Facchini V. Pretreatment plasma levels of Fibrinopeptide-A(FPA), D-dimer(DD), and von Willebrand Factor(vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994; 53: 352 — 6.
- Gaducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996; 60: 197–202.